Get started
Author

Michele F. Mercuri

Observed name: Michele Mercuri
ORCID: 0000-0003-2266-4812
Observed ORCID: 0000-0003-2266-4812
OpenAlex ID: A5137173132
Edoxaban for treatment of venous thromboembolism in patients with cancer
2015 · Marcello Di Nisio, Suzanne M. Bleker, et al. · Thrombosis and Haemostasis · 83
Prediction of Cardiac ATTR Depletion by NI006 ( ALXN2220 ) Using Mechanistic PK / PD Modeling
2024 · Aubin Michalon, Lionel Renaud, et al. · Clinical Pharmacology & Therapeutics · 15
PDF
PA-349 Phase 3 Randomized Trial of Anselamimab Demonstrates Improvement in All-Cause Mortality in κ Light Chain Amyloidosis
2026 · Julia Catini, Ashu Wechalekar, et al. · Clinical Lymphoma Myeloma & Leukemia
Effect of Anselamimab on Cardiac Structure and Function in Patients With Light Chain Amyloidosis: Insights From the CARES Clinical Trials
2026 · Xiaowen Wang, Marianna Fontana, et al. · Circulation
POSTER: MM-218: Phase 3 Randomized Trial of Anselamimab Demonstrates Improvement in All-Cause Mortality in κ Light-Chain Amyloidosis
2026 · Ashutosh Wechalekar, Angela Dispenzieri, et al. · Clinical Lymphoma Myeloma & Leukemia
ORAL ABSTRACT: MM-218: Phase 3 Randomized Trial of Anselamimab Demonstrates Improvement in All-Cause Mortality in κ Light-Chain Amyloidosis
2026 · Ashutosh Wechalekar, Angela Dispenzieri, et al. · Clinical Lymphoma Myeloma & Leukemia
MM-218: Phase 3 Randomized Trial of Anselamimab Demonstrates Improvement in All-Cause Mortality in κ Light-Chain Amyloidosis
2026 · Ashutosh Wechalekar, Angela Dispenzieri, et al. · Clinical Lymphoma Myeloma & Leukemia
Phase 3 randomized trial to evaluate the impact of anselamimab on all-cause mortality in κ light-chain amyloidosis.
2026 · Ashutosh D. Wechalekar, Angela Dispenzieri, et al. · Journal of Clinical Oncology
Works count: 8
Citation count: 98
H-index: 2
I10-index: 2
Year
Topic
Type